TW202342048A - 使用lou064治療化膿性汗腺炎之方法 - Google Patents

使用lou064治療化膿性汗腺炎之方法 Download PDF

Info

Publication number
TW202342048A
TW202342048A TW112107010A TW112107010A TW202342048A TW 202342048 A TW202342048 A TW 202342048A TW 112107010 A TW112107010 A TW 112107010A TW 112107010 A TW112107010 A TW 112107010A TW 202342048 A TW202342048 A TW 202342048A
Authority
TW
Taiwan
Prior art keywords
lou064
treatment
patient
patients
administered
Prior art date
Application number
TW112107010A
Other languages
English (en)
Chinese (zh)
Inventor
索維克 巴塔查亞
布魯諾 比斯
布魯諾 塞尼
戈登 格雷厄姆
麥克 瓊可
克里斯汀 羅斯克
凱瑞 雷普
金賢 善
喬那斯 班傑明 契兒
Original Assignee
瑞士商諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商諾華公司 filed Critical 瑞士商諾華公司
Publication of TW202342048A publication Critical patent/TW202342048A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW112107010A 2022-02-28 2023-02-24 使用lou064治療化膿性汗腺炎之方法 TW202342048A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263314572P 2022-02-28 2022-02-28
US63/314,572 2022-02-28
US202263369016P 2022-07-21 2022-07-21
US63/369,016 2022-07-21

Publications (1)

Publication Number Publication Date
TW202342048A true TW202342048A (zh) 2023-11-01

Family

ID=85570288

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112107010A TW202342048A (zh) 2022-02-28 2023-02-24 使用lou064治療化膿性汗腺炎之方法

Country Status (11)

Country Link
US (1) US20250099465A1 (cg-RX-API-DMAC10.html)
EP (1) EP4486346A1 (cg-RX-API-DMAC10.html)
JP (2) JP7696006B2 (cg-RX-API-DMAC10.html)
KR (1) KR20240155278A (cg-RX-API-DMAC10.html)
CN (1) CN120617264A (cg-RX-API-DMAC10.html)
AU (1) AU2023225222A1 (cg-RX-API-DMAC10.html)
CA (1) CA3251002A1 (cg-RX-API-DMAC10.html)
IL (1) IL314205A (cg-RX-API-DMAC10.html)
MX (1) MX2024010392A (cg-RX-API-DMAC10.html)
TW (1) TW202342048A (cg-RX-API-DMAC10.html)
WO (1) WO2023161887A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250243170A1 (en) * 2024-01-26 2025-07-31 Novartis Ag Remibrutinib drug substance and drug product substantially free of nitrosamine impurity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
WO2017089985A1 (en) 2015-11-26 2017-06-01 Novartis Ag Diamino pyridine derivatives
WO2018055550A1 (en) 2016-09-23 2018-03-29 Novartis Ag Indazole compounds for use in tendon and/or ligament injuries
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
JP2022500408A (ja) * 2018-09-12 2022-01-04 デノボ バイオファーマ エルエルシー エンザスタウリンとbtkの阻害剤との組合せおよびその使用
CN113840821A (zh) * 2019-05-23 2021-12-24 诺华股份有限公司 Btk抑制剂的晶型
US12383556B2 (en) 2019-05-23 2025-08-12 Novartis Ag Methods of treating Sjögren's syndrome using a Bruton's tyrosine kinase inhibitor
FI3972604T3 (fi) 2019-05-23 2025-09-01 Novartis Ag Brutonin tyrosiinikinaasin estäjä käytettäväksi kroonisen spontaanin urtikarian hoidossa
CA3163850A1 (en) * 2020-01-08 2021-07-15 Principia Biopharma Inc. Topical pharmaceutical compositions comprising 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile
EP4284344A1 (en) 2021-01-26 2023-12-06 Novartis AG Pharmaceutical composition

Also Published As

Publication number Publication date
AU2023225222A1 (en) 2024-07-25
JP2025134747A (ja) 2025-09-17
MX2024010392A (es) 2024-09-06
IL314205A (en) 2024-09-01
EP4486346A1 (en) 2025-01-08
JP7696006B2 (ja) 2025-06-19
CN120617264A (zh) 2025-09-12
JP2024511938A (ja) 2024-03-18
WO2023161887A1 (en) 2023-08-31
CA3251002A1 (en) 2023-08-31
US20250099465A1 (en) 2025-03-27
KR20240155278A (ko) 2024-10-28

Similar Documents

Publication Publication Date Title
JP6974669B2 (ja) B−Raf阻害薬、EGFR阻害薬及び場合によってはPI3K−α阻害薬を含む組合せ医薬
KR102258698B1 (ko) B-Raf 억제제와 제2 억제제를 포함하는 조합 요법
JP2023057151A (ja) Aml及びmdsの治療のためのraraアゴニスト
CN107982270A (zh) 治疗乳腺癌的方法
CN116059365A (zh) 对使用维甲酸受体-α激动剂治疗的患者进行分层的方法
WO2020234782A1 (en) Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor
JP2024511141A (ja) オリスミラストによる化膿性汗腺炎の治療
JP2010508277A (ja) 癌を検出および抑制するための方法
Xiang et al. Tiamulin inhibits TNF-α and alleviates psoriasis-like dermatitis
JP2025134747A (ja) 化膿性汗腺炎の治療における使用のためのレミブルチニブ
KR20220088830A (ko) 비뇨기계암의 치료 방법
CN121985949A (zh) 用于治疗溃疡性结肠炎的奥法莫德
KR102675587B1 (ko) 펜벤다졸, 옥시벤다졸 또는 이들의 혼합물을 포함하는 자궁내막 세포 또는 영양막 세포의 비정상적 증식 관련 질환의 예방 또는 치료용 약학적 조성물
JP2024525515A (ja) がんの予防用又は治療用の医薬組成物
Lu et al. Flutamide inhibits nifedipine‐and interleukin‐1β‐induced collagen overproduction in gingival fibroblasts
JP7594124B2 (ja) Lou064を使用した治療の方法
JP2015500221A (ja) 眼疾患の治療および予防方法
EA051701B1 (ru) Ремибрутиниб для применения в лечении гнойного гидраденита
CN118742308A (zh) 用于在治疗化脓性汗腺炎中使用的雷米布鲁替尼
US20250339442A1 (en) Methods of treatment using a dual specificity tyrosine-phosphorylation-regulated kinase 1a (dyrk1a) inhibitor
WO2025217284A1 (en) Methods and compositions for treating inflammatory and autoimmune disorders of the skin
Marren et al. THU0173 Pregnancy Outcomes in the Tofacitinib RA Safety Database Through April 2014
TW202539668A (zh) 使用索樂匹尼布處置免疫性血小板減少症的方法
EA051816B1 (ru) Способы лечения с применением lou064
JP2021511380A (ja) 腫瘍増殖を抑制するためのミナプリンの使用